Loading...
Market
What will be the primary outcome of the experimental lung cancer vaccine trial by August 23, 2025?
2
Resolution / Starting Odds
Significant tumor shrinkage • 25%
Improved survival rates • 25%
No significant effect • 25%
Other • 25%
Final trial results published in medical journals or official announcements from the trial organizers
Story
UK Patient First to Receive Experimental Lung Cancer Vaccine in Global Trial
Aug 23, 2024, 04:19 AM
A lung cancer patient in the UK has become the first to receive an experimental vaccine as part of a world-first trial. This pioneering trial, conducted across seven countries, aims to explore new treatments for lung cancer. The patient, whose cancer was found by coincidence, received the vaccine at UCLH. This development offers hope in the fight against the disease, marking a significant step in medical research. The trial has garnered attention and is featured on the front page of several publications, highlighting its potential impact on future cancer treatments.
View original story
Similar markets
Significant survival improvement • 25%
Partial survival improvement • 25%
No significant change • 25%
Deterioration • 25%
Successful with significant improvement in survival rates • 25%
Successful with moderate improvement in survival rates • 25%
No significant improvement in survival rates • 25%
Trial halted due to adverse effects • 25%
Yes • 50%
No • 50%
Successful with significant results • 25%
Moderate success with some positive results • 25%
No significant results • 25%
Trial halted or inconclusive • 25%
Positive • 25%
Negative • 25%
Mixed • 25%
Not published • 25%
Yes • 50%
No • 50%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
Significant Improvement • 33%
No Change • 33%
Significant Adverse Effects • 34%
Positive - Significant survival improvement • 25%
Neutral - No significant difference • 25%
Negative - Worse outcomes • 25%
Trial inconclusive • 25%
Yes • 50%
No • 50%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%